MUC1 peptide vaccine study for non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a vaccine made from a lung-cancer target (MUC1) to help your immune system recognize and fight the cancer. It is designed to measure immune response and safety, and it may help some people develop a stronger anti-cancer immune reaction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer or a specific lung tumor type (neuroendocrine carcinoid), confirmed by pathology (tissue or fluid testing)
- Your cancer is in an eligible stage and is not getting worse right now (stable disease)
- You are 18 or older, and your day-to-day ability is good (ECOG 0–1)
- You finished standard treatment recently—typically between 4 and 24 weeks, and not more than 24 weeks ago
- Your blood counts and organ function are within acceptable lab ranges (white blood cells, neutrophils, hemoglobin, platelets, kidney and liver tests)
- If you can become pregnant, you must use effective birth control during the study and for at least 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine, given alone or with an immunotherapy drug called toripalimab, in people with non-small cell lung cancer (NSCLC) who have had surgery and are getting adjuvant therapy (treatment to prevent the cancer from coming back). The goal is to see if the vaccine is safe and may help the immune system fight any remaining cancer cells.
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.